The number of U.S. women with breast cancer that has spread elsewhere in the body by the time of diagnosis increased ...

TUESDAY, Dec. 10, 2024 (HealthDay News) -- More breast cancers are being detected later in women, giving the tumors a chance ...

The rates of life-threatening breast cancer are spiking among women of all ages, with a significant increase in those under ...

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months ...

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...

The number of women with late-stage, invasive breast cancer at the time of diagnosis increased significantly among U.S. women ...

About Zetagen Therapeutics Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company ...

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

Acceptance and commitment therapy (ACT) significantly decreased fatigue interference and improved quality of life in patients ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...